BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19825989)

  • 1. H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.
    Francis H; Onori P; Gaudio E; Franchitto A; DeMorrow S; Venter J; Kopriva S; Carpino G; Mancinelli R; White M; Meng F; Vetuschi A; Sferra R; Alpini G
    Mol Cancer Res; 2009 Oct; 7(10):1704-13. PubMed ID: 19825989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway.
    Francis H; Franchitto A; Ueno Y; Glaser S; DeMorrow S; Venter J; Gaudio E; Alvaro D; Fava G; Marzioni M; Vaculin B; Alpini G
    Lab Invest; 2007 May; 87(5):473-87. PubMed ID: 17334413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway.
    Fava G; Marucci L; Glaser S; Francis H; De Morrow S; Benedetti A; Alvaro D; Venter J; Meininger C; Patel T; Taffetani S; Marzioni M; Summers R; Reichenbach R; Alpini G
    Cancer Res; 2005 Dec; 65(24):11437-46. PubMed ID: 16357152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.
    Fava G; Demorrow S; Gaudio E; Franchitto A; Onori P; Carpino G; Glaser S; Francis H; Coufal M; Marucci L; Alvaro D; Marzioni M; Horst T; Mancinelli R; Benedetti A; Alpini G
    Liver Int; 2009 Aug; 29(7):1031-42. PubMed ID: 19291182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway.
    Francis H; Glaser S; Demorrow S; Gaudio E; Ueno Y; Venter J; Dostal D; Onori P; Franchitto A; Marzioni M; Vaculin S; Vaculin B; Katki K; Stutes M; Savage J; Alpini G
    Am J Physiol Cell Physiol; 2008 Aug; 295(2):C499-513. PubMed ID: 18508907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
    Francis H; DeMorrow S; Venter J; Onori P; White M; Gaudio E; Francis T; Greene JF; Tran S; Meininger CJ; Alpini G
    Gut; 2012 May; 61(5):753-64. PubMed ID: 21873469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.
    Kamenz T; Caca K; Blüthner T; Tannapfel A; Mössner J; Wiedmann M
    World J Gastroenterol; 2006 Mar; 12(10):1583-90. PubMed ID: 16570351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
    Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis.
    Onori P; DeMorrow S; Gaudio E; Franchitto A; Mancinelli R; Venter J; Kopriva S; Ueno Y; Alvaro D; Savage J; Alpini G; Francis H
    Int J Cancer; 2009 Aug; 125(3):565-76. PubMed ID: 19358267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
    Hidalgo M; Amador ML; Jimeno A; Mezzadra H; Patel P; Chan A; Nielsen ME; Maitra A; Altiok S
    Mol Cancer Ther; 2006 Jul; 5(7):1895-903. PubMed ID: 16891476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways.
    Alpini G; Kanno N; Phinizy JL; Glaser S; Francis H; Taffetani S; LeSage G
    Am J Physiol Gastrointest Liver Physiol; 2004 Jun; 286(6):G973-82. PubMed ID: 14701718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.
    DeMorrow S; Onori P; Venter J; Invernizzi P; Frampton G; White M; Franchitto A; Kopriva S; Bernuzzi F; Francis H; Coufal M; Glaser S; Fava G; Meng F; Alvaro D; Carpino G; Gaudio E; Alpini G
    Am J Physiol Cell Physiol; 2011 May; 300(5):C1078-89. PubMed ID: 21270292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
    Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
    Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2+-dependent protein kinase C-alpha.
    Kanno N; Glaser S; Chowdhury U; Phinizy JL; Baiocchi L; Francis H; LeSage G; Alpini G
    J Hepatol; 2001 Feb; 34(2):284-91. PubMed ID: 11281558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor.
    Mancino A; Mancino MG; Glaser SS; Alpini G; Bolognese A; Izzo L; Francis H; Onori P; Franchitto A; Ginanni-Corradini S; Gaudio E; Alvaro D
    Dig Liver Dis; 2009 Feb; 41(2):156-63. PubMed ID: 18395502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histamine H
    Aquino-Miranda G; Rivera-Ramírez N; Márquez-Gómez R; Escamilla-Sánchez J; González-Pantoja R; Ramos-Languren LE; Perez-Neri I; Bueno-Nava A; Ríos C; Arias-Montaño JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109653. PubMed ID: 31108178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
    Zhao YY; Jia J; Zhang JJ; Xun YP; Xie SJ; Liang JF; Guo HG; Zhu JZ; Ma SL; Zhang SR
    Acta Pharmacol Sin; 2021 Aug; 42(8):1288-1297. PubMed ID: 33159174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.